NLP-2 (TRZ)
Synthetic 39-amino acid dual agonist peptide with binding affinity for GIP and GLP-1 receptor subtypes, incorporating a C20 fatty diacid moiety for extended albumin binding. Lyophilized, mass-spec certified, research-grade.
Third-party tested, batch-by-batch
Every lot is independently verified for identity (MS), purity (HPLC), appearance, and endotoxin. View the summary for the current lot, or request the full signed PDF by email.
Frequently researched together
Technical specifications
NLP-2 (TRZ) is a synthetic 39-amino acid peptide engineered as a dual agonist of the glucose-dependent insulinotropic polypeptide (GIP) receptor and the glucagon-like peptide-1 (GLP-1) receptor — two incretin hormone receptors of the class B G-protein-coupled receptor family. GIP and GLP-1 are incretin hormones secreted from intestinal K-cells and L-cells respectively in response to nutrient ingestion, and their receptors are expressed across pancreatic islets, the central nervous system, and adipose tissue. The peptide carries a C20 fatty diacid moiety conjugated near the Lys20 residue, which enables reversible binding to serum albumin and extends the circulating half-life in pharmacokinetic model studies. Receptor pharmacology studies describe the molecule as an "imbalanced" and biased agonist — engaging the GIP receptor to a greater degree than the GLP-1 receptor, and preferentially driving cAMP signaling over β-arrestin recruitment at the GLP-1 receptor. As a research compound it is used to study dual-incretin receptor binding kinetics, comparative signal transduction, and incretin-axis pharmacology in vitro and in preclinical models.
- Single 39-amino acid peptide that activates both the GIP and GLP-1 receptors — two distinct incretin hormone receptors — from one molecule
- GIP (glucose-dependent insulinotropic polypeptide) and GLP-1 (glucagon-like peptide-1) are incretin hormones secreted by intestinal K-cells and L-cells; both receptors are class B G-protein-coupled receptors
- A C20 fatty diacid moiety conjugated near Lys20 promotes reversible serum-albumin binding, extending circulating half-life in pharmacokinetic model studies
- Characterized in receptor pharmacology studies as an "imbalanced" agonist — greater engagement of the GIP receptor than the GLP-1 receptor — with biased GLP-1 receptor signaling favoring cAMP generation over β-arrestin recruitment
- The peptide backbone is derived from the GIP sequence with substitutions that add GLP-1 receptor activity and increase resistance to dipeptidyl peptidase IV (DPP-IV) degradation
- Studied in published clinical research (the SURPASS and SURMOUNT trial programs) using pharmaceutical-grade formulations under clinical trial conditions, which are distinct from this RUO compound
- Lyophilized; reconstituted with bacteriostatic water for in vitro or animal model studies
- For research use only — not for human or veterinary administration
Peer-reviewed research
All products sold by Next Level Research LLC are intended for laboratory and research use only. Not for human or animal consumption. Not a drug, food, or cosmetic. No therapeutic claims are made.